Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KC1036 in Advanced Recurrent or Metastatic Thymic Tumors
NCT05683886Phase 2Recruiting
- Sponsor
- Beijing Konruns Pharmaceutical Co., Ltd.
- Start
- Feb 2023
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of connitinib in thymoma, thymic carcinoma (TC), sponsored by Beijing Konruns Pharmaceutical Co., Ltd.. Started Feb 2023; status: recruiting.
02
Drugs
connitinib
03
Conditions
thymomathymic carcinoma (TC)
Beyond the preview
Go deeper on NCT05683886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05683886.